Skip to main content

Table 2 Summary of NADC and ADC reported in the D:A:D study from 2004-2010

From: Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

 

n (% of total events)

Number of NADC events

880 (100.0)

Lung cancer

140 (15.9)

Hodgkin’s lymphoma

112 (12.7)

Anal cancer

79 (9.0)

Head and neck cancers

71 (8.1)

Liver cancer

59 (6.7)

Prostate

57 (6.5)

Breast cancer

43 (4.9)

Malignant melanoma

31 (3.5)

Colon cancer

26 (3.0)

Bladder cancer

21 (2.4)

Rectal

20 (2.3)

Gynecological cancers*

14 (1.6)

Stomach

13 (1.5)

Penile cancer

12 (1.4)

Kidney cancers

12 (1.4)

Acute myeloid leukemia

11 (1.3)

Metastasis of adenocarcinoma

9 (1.0)

Testicular

9 (1.0)

Lip cancer

6 (0.7)

Uterus

5 (0.6)

Brain cancer

5 (0.6)

Multiple myeloma

5 (0.6)

Metastasis of other cancer type

5 (0.6)

Metastasis of squamous cell carcinoma

5 (0.6)

Metastasis unspecified

4 (0.5)

Chronic lymphatic leukemia

2 (0.2)

Chronic myeloid leukemia

2 (0.2)

Connective tissue cancer

2 (0.2)

Bone cancer

1 (0.1)

Acute lymphatic leukemia

1 (0.1)

Leukemia unspecified

1 (0.1)

Type unknown

8 (0.9)

Unknown primary cancer

7 (0.8)

Other**

82 (9.3)

Number of ADC events

621 (100.0)

Kaposi’s sarcoma

331 (53.3)

Non-Hodgkin’s lymphoma

251 (40.4)

Cervical carcinoma

46 (7.4)

  1. *Other than uterus and cervical cancer.
  2. **Esophageal cancer, pancreas cancer, gall bladder cancer.